Corporate | 23 April 2008 11:35
STRATEC Biomedical Systems AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
STRATEC presents new results of nucleic acid stabilization technology
Birkenfeld, April 23, 2008
STRATEC Biomedical Systems AG, Birkenfeld, Germany, will be presenting the
latest results of its nucleic acid stabilization technology at the 24th
Annual Clinical Virology Symposium of the Pan American Society for Clinical
Virology to be held in Daytona Beach, Florida, USA, at the end of April.
The results focus on a standardized solution for blood analysis, whose
features include freezing the virus concentration in the blood sample in
the moment at which the blood is drawn from the patient, stabilizing the
nucleic acid of the viruses and simultaneously deactivating the viruses.
Experiments carried out with a large number of further virus strains have
proven the universal applicability of this nucleic acid stabilization
technology, which is known as MRT – Modified RNA Technology.
Stabilizing the nucleic acid of viruses and neutralizing the infectiousness
of potentially infectious blood samples upon withdrawal improves the safety
of laboratory personnel when handling potentially infectious samples. The
stabilized sample materials' low degree of susceptibility to environmental
influences, such as overly high temperatures, and the increased safety
resulting from virus inactivation enable the costs of storing and
transporting sample material to be drastically reduced.
The results have been confirmed by two further independent university
cooperation partners.
The STRATEC Group owns worldwide exclusive rights to this patented
technology for the stabilization and purification of nucleic acid from
pathogens for diagnostic and other applications. In line with STRATEC’s
business model, the company plans to market the technology as system
solutions together with an existing STRATEC analyzer via its OEM partners.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated analyzer systems for its partners in the
fields of clinical diagnostics and biotechnology. These partners market
such systems, in general together with their own reagents, to laboratories,
blood banks and research institutes around the world. The company develops
its products on the basis of its own patented technologies. Shares in the
company (ISIN: DE0007289001) are traded in the Prime Standard segment of
the Frankfurt Stock Exchange and on other exchanges.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Rumania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr.37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-Mail: ir@stratec-biomedical.de
23.04.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------